Alembic Ltd
Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group.
With its registered office in Vadodra, Alembic Ltd currently holds a 28.41% stake in Alembic Pharma Ltd and a 19.01% stake in another group entity Paushak Limited.[1]
- Market Cap ₹ 2,258 Cr.
- Current Price ₹ 87.9
- High / Low ₹ 117 / 70.5
- Stock P/E 19.0
- Book Value ₹ 32.0
- Dividend Yield 2.73 %
- ROCE 16.9 %
- ROE 14.2 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 53.1%
Cons
- Earnings include an other income of Rs.72.8 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Consumer Discretionary Realty Realty Residential, Commercial Projects
Part of BSE Consumer Discretionary BSE 1000
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 144 | 134 | 147 | 125 | 124 | 74 | 72 | 76 | 123 | 152 | 214 | 232 | |
| 134 | 128 | 140 | 114 | 106 | 70 | 62 | 63 | 85 | 96 | 125 | 144 | |
| Operating Profit | 10 | 6 | 7 | 11 | 18 | 4 | 11 | 13 | 38 | 56 | 90 | 88 |
| OPM % | 7% | 5% | 5% | 9% | 15% | 5% | 15% | 17% | 31% | 37% | 42% | 38% |
| 21 | 25 | 25 | 37 | 29 | 93 | 10 | 89 | 54 | 55 | 75 | 73 | |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Depreciation | 6 | 6 | 5 | 4 | 3 | 3 | 4 | 4 | 6 | 7 | 10 | 12 |
| Profit before tax | 23 | 25 | 27 | 44 | 45 | 94 | 17 | 97 | 85 | 103 | 152 | 147 |
| Tax % | -3% | 2% | -3% | 5% | 8% | 0% | 19% | 12% | 7% | 10% | 7% | 15% |
| 24 | 25 | 27 | 42 | 41 | 94 | 13 | 86 | 79 | 93 | 142 | 125 | |
| EPS in Rs | 0.90 | 0.93 | 1.03 | 1.56 | 1.60 | 3.64 | 0.52 | 3.34 | 3.09 | 3.62 | 5.53 | 4.85 |
| Dividend Payout % | 17% | 16% | 19% | 13% | 12% | 16% | 38% | 54% | 71% | 66% | 43% | 49% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 26% |
| 3 Years: | 23% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 65% |
| 3 Years: | 11% |
| TTM: | -16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -7% |
| 3 Years: | 5% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 12% |
| 3 Years: | 14% |
| Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 53 | 53 | 53 | 53 | 51 | 51 | 51 | 51 | 51 | 51 | 51 | 51 |
| Reserves | 211 | 295 | 314 | 395 | 361 | 432 | 775 | 962 | 778 | 757 | 802 | 770 |
| 0 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 14 | 11 | |
| 91 | 64 | 81 | 73 | 57 | 51 | 109 | 130 | 119 | 128 | 142 | 126 | |
| Total Liabilities | 356 | 421 | 449 | 522 | 470 | 534 | 936 | 1,144 | 948 | 946 | 1,010 | 958 |
| 169 | 146 | 171 | 179 | 209 | 225 | 261 | 294 | 318 | 366 | 406 | 470 | |
| CWIP | 2 | 0 | 0 | 0 | 0 | 3 | 6 | 0 | 0 | 1 | 0 | 2 |
| Investments | 35 | 150 | 189 | 276 | 205 | 197 | 581 | 726 | 503 | 411 | 414 | 349 |
| 149 | 124 | 89 | 67 | 55 | 109 | 88 | 124 | 127 | 168 | 190 | 138 | |
| Total Assets | 356 | 421 | 449 | 522 | 470 | 534 | 936 | 1,144 | 948 | 946 | 1,010 | 958 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 | 10 | 52 | 24 | 22 | 5 | -1 | -22 | 35 | 25 | 81 | 117 | |
| 5 | -5 | -47 | -23 | 68 | 57 | -35 | 23 | 11 | 23 | -22 | -52 | |
| -25 | -5 | -5 | -3 | -89 | -6 | -15 | -6 | -46 | -48 | -58 | -67 | |
| Net Cash Flow | 2 | -0 | -0 | -2 | 1 | 56 | -52 | -5 | -0 | 0 | 2 | -1 |
| Free Cash Flow | 22 | 11 | 38 | 14 | -1 | -16 | -44 | -55 | 10 | -31 | 30 | 41 |
| CFO/OP | 222% | 172% | 771% | 246% | 145% | 187% | 8% | -102% | 108% | 42% | 107% | 156% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 122 | 76 | 54 | 74 | 40 | 44 | 66 | 72 | 67 | 42 | 47 | 48 |
| Inventory Days | 880 | 659 | 438 | 247 | 289 | 411 | 2,112 | 2,885 | 5,118 | 3,694 | 1,161 | |
| Days Payable | 200 | 144 | 128 | 125 | 202 | 151 | 675 | 635 | 993 | 1,213 | 510 | |
| Cash Conversion Cycle | 801 | 591 | 364 | 195 | 126 | 304 | 1,504 | 2,322 | 4,191 | 2,523 | 47 | 698 |
| Working Capital Days | 235 | 172 | 39 | 20 | 13 | 28 | 96 | 231 | 127 | 75 | 58 | -2 |
| ROCE % | 9% | 8% | 8% | 10% | 10% | 21% | 2% | 10% | 10% | 12% | 18% | 17% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Sep 2022 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Stake in Alembic Pharmaceuticals Limited % |
|
|||||
| Co-generation power installed capacity MW |
||||||
| Land bank acres |
||||||
| Wind power installed capacity MW |
||||||
| Permanent workforce count |
||||||
| Real estate project bookings % |
||||||
| R&D Expenditure (Percentage of Turnover) % |
||||||
Extracted by Screener AI
Documents
Announcements
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015
13 Jul - Alembic Ltd schedules 119th AGM on 11 Aug 2026; final dividend record date 4 Aug 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Jul - A copy of the notice published in Indian Express (English Edition) and Financial Express (Gujarati Edition - vernacular language) on 11th July, 2026 inter ....
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Jul - Regulation 74(5) certificate for quarter ended 30 June 2026 received from MUFG Intime.
-
Business Responsibility and Sustainability Reporting (BRSR)
10 Jul - Alembic Ltd submitted FY2025-26 Business Responsibility and Sustainability Report on 10 July 2026.
- Intimation Of Record Date For Payment Of Dividend On Equity Shares For The Financial Year Ended 31St March, 2026 10 Jul
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Segments:[1]
a) Real Estate (81% in FY26 vs 85% in FY25):[2]
The company develops residential and commercial real estate projects, provides
project management and marketing consultancy services and generates rental income by leasing commercial properties.